Yuki Noguchi
👤 SpeakerAppearances Over Time
Podcast Appearances
Previously, such assessments were only possible by surgically removing the lymph nodes.
The research appears in the Journal of Clinical Oncology.
Technologies like this are improving survival and quality of life after a diagnosis.
Roughly half of those who take GLP-1s lose 15% or more of their body weight.
But a minority, about one in six, lose very little.
Doctors specializing in obesity care say this is because dozens of factors can contribute to a person's obesity.
And the new class of popular medicines may not address a person's particular biology.
Dr. Jennifer Manny Guler is a specialist at Harvard.
One tool often is not enough over the lifetime of a person to control or to mitigate the health impact of that condition.
But in a few years, she says, genetic and other tests will make it easier to personalize those treatments.
The White House has been pressuring drug makers to equalize U.S.
pricing with other countries.
The administration says these agreements will lower Medicaid drug prices.
Consumers who pay out-of-pocket will also be able to get lower prices for some of the company's most popular drugs through a government website called TrumpRx.
Under the agreements, Amgen, Merck, GSK, and others will also invest $150 billion in U.S.
In exchange, the companies will be exempt from some of the administration's stiff tariffs for three years.